| Animal models of cannabinoid reward. | |
| | |
MedLine Citation:
|
PMID: 20590560 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The endogenous cannabinoid system is involved in numerous physiological and neuropsychological functions. Medications that target this system hold promise for the treatment of a wide variety of disorders. However, as reward is one of the most prominent of these functions, medications that activate this system must be evaluated for abuse potential. Meanwhile, cannabis is already being used chronically by millions of people, many of whom eventually seek treatment for cannabis dependence. Therefore, there is a need for procedures that can be used to: (i) better understand the mechanisms of cannabinoid reward; (ii) evaluate the abuse potential of new medications; and (iii) evaluate the effectiveness of medications developed for treating cannabis dependence. Animal models of cannabinoid reward provide a means of accomplishing these goals. In this review, we briefly describe and evaluate these models, their advantages and their shortcomings. Special emphasis is placed on intravenous cannabinoid self-administration in squirrel monkeys, a valid, reliable and flexible model that we have developed over the past decade. Although the conditions under which cannabinoid drugs have rewarding effects may be more restricted than with other drugs of abuse such as cocaine and heroin, work with these models indicates that cannabinoid reward involves similar brain mechanisms and produces the same kinds of reward-related behaviour. By continuing to use these animal models as tools in the development of new medications, it should be possible to take advantage of the potential benefits provided by the endocannabinoid system while minimizing its potential for harm. |
| | |
Authors:
|
Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: British journal of pharmacology Volume: 160 ISSN: 1476-5381 ISO Abbreviation: Br. J. Pharmacol. Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-07-01 Completed Date: 2010-10-14 Revised Date: 2012-02-22 |
Medline Journal Info:
|
Nlm Unique ID: 7502536 Medline TA: Br J Pharmacol Country: England |
Other Details:
|
Languages: eng Pagination: 499-510 Citation Subset: IM |
Affiliation:
|
Preclinical Pharmacology Section, Behavioral Neuroscience Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, MD 21224, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Cannabinoids / administration & dosage, adverse effects*, pharmacology* Disease Models, Animal* Drug Discovery / methods Drug Evaluation, Preclinical / methods* Endocannabinoids / physiology* Humans Reward* Self Administration Substance-Related Disorders / psychology* |
| Grant Support | |
ID/Acronym/Agency:
|
N01 DA059909/DA/NIDA NIH HHS; Z99 DA999999/DA/NIDA NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Cannabinoids; 0/Endocannabinoids |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The endocannabinoid system as a target for the treatment of neurodegenerative disease.
Next Document: Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models.